Gene-Marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 20 (1) , 1-9
- https://doi.org/10.1023/a:1006673408343
Abstract
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.Keywords
This publication has 34 references indexed in Scilit:
- Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain.Journal of Clinical Investigation, 1998
- T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patientsBone Marrow Transplantation, 1998
- Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot studyBone Marrow Transplantation, 1997
- B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events.Journal of Clinical Investigation, 1996
- The T cell enigma in lupusArthritis & Rheumatism, 1996
- Characterization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus ErythematosusClinical Immunology and Immunopathology, 1995
- Improved green fluorescenceNature, 1995
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993
- Human gene therapy comes of ageNature, 1992
- Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures.Journal of Clinical Investigation, 1992